Trials
Search / Trial NCT06440083

Pre-warning Risk Scoring System for Sudden Cardiac Death

Launched by SUN YAT-SEN MEMORIAL HOSPITAL OF SUN YAT-SEN UNIVERSITY · May 28, 2024

Trial Information

Current as of February 12, 2025

Recruiting

Keywords

Sudden Cardiac Death Cohort Study

ClinConnect Summary

This clinical trial is looking to find ways to predict sudden cardiac death (SCD) by studying various health indicators. Researchers will examine different tests and measurements, like blood tests, heart scans, and genetic factors, to see if they can create a system that helps identify individuals at risk for SCD early on. The goal is to develop a better screening process that could save lives by catching potential problems before they become serious.

To participate in this study, individuals should be at least 16 years old and have been diagnosed with one or more heart-related conditions, such as coronary heart disease or heart failure. If you or a loved one has a history of these issues, you may be eligible to join. Participants will need to sign a consent form and will be asked to attend follow-up visits to monitor their health. The trial is currently recruiting patients of all genders, making it an inclusive opportunity for those who meet the criteria.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • The subjects with the following diagnosis of one or more cardiovascular diseases:
  • 1. Coronary heart disease If there is a history of coronary heart disease or a new diagnosis of coronary heart disease, or with a report of coronary angiography that indicates at least one vascular stenosis\>50%. Diagnosis includes chronic coronary syndrome (stable angina, ischemic cardiomyopathy, and occult coronary heart disease) and acute coronary syndrome (unstable angina, ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction).
  • 2. Heart failure Individuals with a history of heart failure or newly diagnosed heart failure, including heart failure with reduced ejection fraction (HFrEF, left ventricular ejection fraction (LVEF) ≤40%)、intermediate heart failure (HFmrEF, LVEF 41%-49%,with evidence of spontaneous or excitable increase in left ventricular filling pressure), and ejection fraction preserving heart failure (HFpEF, LVEF≥50%, there is evidence of spontaneous or excitable increase in left ventricular filling pressure).
  • 3. Genetically related cardiomyopathy or arrhythmia Cardiomyopathy includes hypertrophic cardiomyopathy (DCM), dilated cardiomyopathy (HCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), inflammatory cardiomyopathy (myocarditis, sarcoidosis, Chagas disease). Hereditary arrhythmias include long QT syndrome, short QT syndrome, Brugada syndrome, idiopathic ventricular fibrillation, catecholamine sensitive polymorphic ventricular tachycardia (CPVT), early repolarization syndrome, etc.
  • 2) Sign an informed consent form.
  • Exclusion Criteria:
  • 1. Age\<16 years old;
  • 2. Refusal to the follow-up visits;
  • 3. Individuals with severe mental disorders who are unable to express their wishes;
  • 4. Other obvious physical diseases and abnormal laboratory test results;
  • 5. Patients deemed unsuitable for participation in this study by the supervising physician.

Trial Officials

Jingfeng Wang, M.D.,Ph.D.

Principal Investigator

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

About Sun Yat Sen Memorial Hospital Of Sun Yat Sen University

Sun Yat-sen Memorial Hospital of Sun Yat-sen University is a leading academic medical institution located in Guangzhou, China, renowned for its commitment to advancing healthcare through innovative clinical research and patient-centered care. As a prominent sponsor of clinical trials, the hospital leverages its extensive expertise in various medical fields, including oncology, cardiology, and infectious diseases, to conduct rigorous studies aimed at improving treatment outcomes and enhancing patient welfare. With a focus on collaboration and scientific excellence, the hospital is dedicated to translating research findings into practical applications that benefit both local and global communities.

Locations

Guanzhou, Guangdong, China

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0